Rationale: Only 4.5% of brown tumors involve facial bones; of these, solitary bone involvement is usual. Brown tumors of multiple facial bones are extremely rare. Here, we report the case of a brown tumor of multiple facial bones initially misdiagnosed as an odontogenic cyst.
Introduction
Brown tumors are rare giant-cell lesions which result from abnormally high parathyroid hormone levels (hyperparathyroidism [HPT] ). All forms of HPT (primary, secondary, and tertiary) are associated with hyperparathyroid bone disease, which manifests as slowly enlarging painful masses or fractures. Primary HPT is characterized by abnormal parathyroid hormone secretion and has an annual worldwide incidence of approximately 5 in 10, 000 people, most of whom are women aged 60 years or older. [1] Co-occurrence of HPT and brown tumors is now rare due to routine screening for serum calcium in recent years. [2] Nearly 85% of cases are caused by benign parathyroid tumors, and a fewer than 1% by parathyroid malignancies. [3] The common brown tumor sites are the long bones, such as the ribs, clavicles, tibia, and pelvic girdle. Although tumors of the head and neck are rare, when they occur, the mandible is usually involved. [4] Concurrent involvement of multiple facial bones is exceptional. Here, we present the case of 26-year-old woman with painful swelling of multiple facial bones caused by a brown tumor. Despite investigations, including biopsy, the patient was initially not diagnosed with HPT. Therefore, in order to make an accurate diagnosis, HPT should be considered when multiple cystic lesions are located in the facial bones.
Case report
A 26-year-old woman was referred to our hospital with painful swelling of multiple facial bones and limited mouth opening. The patient was 5-months pregnant. She reported that, 3 months before seeking medical attention, she noticed swelling of the left mandible that continued to increase in size and caused constant pain, occasional hemorrhages, and malocclusion. She had a history of rib fracture 5 years previously and pelvic bone fracture 7 years previously. A painless mass in the arterial neck region around the thyroid-cartilage level was noted 2 years previously. Her family history was not significant.
Intraoral examination revealed 1.5 cm Â 1.5 cm and 4 cm Â 2 cm painless sessile swellings on the posterior region of the left maxilla and the retromolar area of the left mandible, respectively. These masses had expanded buccolingually and the oral mucosa was ulcerated and purplish-red; 37, 38 were mobile. There was no lymphadenopathy in the submandibular region on palpation, but a 1.5 cm Â 1 cm node was found at the level of the thyroid cartilage.
Laboratory tests revealed an elevated serum calcium level of 3.09 mmol/L (normal range: 2.0-2.8 mmol/L) and a low phosphorus level of 0.62 mmol/L (normal range: 0.81-1.65 mmol/L). The serum alkaline phosphatase concentration was 397 IU/L (normal range: 24-82 IU/L). Subsequent examination revealed a parathyroid hormone (PTH) level of 267 pg/mL (normal range: 14-72 pg/mL). Plain radiographs of the chest showed multiple osteolytic lesions in the right sixth to tenth ribs and a 5.9 cm Â 4 cm oval calcified nodule in the right upper abdomen (Fig. 1) .
Cone beam computed tomography (CBCT) of the skull revealed a 1.8 cm Â 1.7 cm Â 1.4 cm expansile lucent lesion on the left maxilla. This destructive osteolytic lesion had expanded into the buccolingual bone. The cortex of the mandible was thin bilaterally and the lesion extended from the molar alveolar process into the ramus (Fig. 2 ).
An excisional biopsy was performed on the left mandible. Pathological analysis revealed abundant spindle cells with areas of hemorrhage and haphazardly arranged diffuse multinucleated giant cells (Fig. 3) .
The patient was referred to the endocrine department of a general hospital for further treatment and a parathyroidectomy was performed. Histopathological examination confirmed a parathyroid adenoma. The patient reported marked absence of pain and serum calcium levels underwent an uneventful recovery. Noticeable recalcification of the osteolytic lesion was noted during follow-up.
Discussion
Although brown tumors have been reported extensively, only 4.5% of reported cases have involved the facial bones. [5] Tumors of the maxillofacial region are more likely to affect women than men, with a reported female: male ratio of approximately 1.7:1 and mean age at diagnosis of 34 years. [6] Maxillofacial tumors usually involve solitary bones, with the mandible being the most frequently affected. [7] Tumors may cause loosening and displacement of the teeth, resultant malocclusion, and facial deformity. Patients are often referred to hospital complaining of painful bone swelling or of loose teeth. Associated symptoms, which are caused by elevated serum calcium levels, include anorexia, nausea, vomiting, constipation, fatigue, and urinary calculi.
Our patient presented with a particularly interesting case of brown tumor caused by primary HPT. First, multiple facial bones were involved, which is extremely rare and could be confused with odontogenic cysts or tumors, bone metastasis, or multiple myeloma. [8] The radiological diversity of brown tumors makes accurate diagnosis via imaging challenging. Brown tumors are benign reactive osteolytic lesions rather than true neoplasms. Some brown tumors have sclerotic margins, while others are expansive soft tissue masses which cause cortical destruction. Moreover, the radiological appearance of the lesions may vary according to the stage of HPT. The presence of a sclerotic margin makes it easier to exclude bone metastasis but rather difficult to exclude odontogenic cysts or tumors. However, some tumors which present as soft tissue masses with cortical destruction may mimic malignant tumors.
A fewer than 5% of cases of primary HPT with multiple maxillofacial bone involvement are diagnosed as primary hyperparathyroidism-jaw tumor syndrome (HPT-JT). [9] This syndrome is characterized by the presence of primary HPT, ossifying fibroma of the mandible and maxilla, and, occasionally, renal tumors and uterine fibroids. It is an autosomal dominant disorder associated with mutations of the CDC73 gene. Approximately 80% of HPT-JT patients have primary HPT and the average age at diagnosis is 32 years. [10] Genetic sequencing for CDC73, screening for renal and uterine tumors, and a detailed review of family history would be beneficial for young HPT patients with multiple-facial-bone involvement. Our patient had no family history of primary HPT, so we did not perform genetic tests.
Second, tumor growth was accelerated due to the patient's pregnancy, and many of her clinical symptoms, which included anorexia, nausea, vomiting, constipation, and fatigue, had been incorrectly attributed to her pregnancy at previous hospital visits.
A diagnosis of brown tumor should be based on elevated serum calcium, alkaline phosphatase and parathyroid hormone levels, low serum phosphate levels, and histological features. Computed tomography or bone scans are helpful in making a differential diagnosis and identifying the extent of the lesion. Although fine needle aspiration biopsy has been used to diagnose brown tumors, [11] it poses the risk of uncontrolled local hemorrhage, which unfortunately occurred in our case.
Primary HPT is usually cured by parathyroidectomy. After surgery, excessive parathyroid hormone levels return to normal and osteolytic lesions are gradually re-mineralized without surgery, [12] which was the case with our patient.
Conclusion
Multiple osteolytic lesions of facial bones are common in patients attending maxillofacial clinics. Although the incidence of brown tumors resulting from primary HPT is very low, they should be included in a differential diagnosis of odontogenic cysts or tumors, bone metastasis, or multiple myeloma. This report highlights the importance of reviewing the patient's history to guide appropriate investigations and aid diagnosis. Serum calcium and parathyroid hormone assays should be performed routinely for multiple osteolytic lesions. Such an approach will reduce the rate of misdiagnosis of this disease, avoid unnecessary harm to patients, and enable appropriate treatment to be given.
